Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Investors seeking all of the latest and greats stock market stories for Friday will find them in our daily roundup.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

The company’s racing to get its newest obesity drug to market. 


U.S. Regulators Pushed to Fast-Track Approval of Eli Lilly’s Weight-Loss Pill: Reports

Danish drugmaker Novo Nordisk ($NVO) launched its blockbuster diabetes treatment Ozempic (semaglutide injection) in India at an entry price of $24....

Novo Nordisk (NVO) Launches Blockbuster Diabetes Drug Ozempic in India

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk today and set a price target of DKK475.00. Papadakis covers the He...

Novo Nordisk (0QIU) Receives a Buy from Deutsche Bank

UBS analyst Matthew Weston maintained a Hold rating on Novo Nordisk today and set a price target of DKK295.00. According to TipRanks, Weston is a 4...

UBS Remains a Hold on Novo Nordisk (0QIU)

The pharma giant has high hopes for the medication. 


Eli Lilly’s (LLY) Newest Weight-Loss Drug Delivers Strong Results in Late-Stage Trial

Hims & Hers Health ($HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will also include the offic...

Hims & Hers Health (HIMS) Bolsters UK Business with Launch of Weight-Loss Plans

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk today and set a price target of DKK352.00. Quigley covers the Healthcar...

Goldman Sachs Sticks to Their Buy Rating for Novo Nordisk (0QIU)

Biotech Structure Therapeutics’ ($GPCR) shares rallied 102.49% on Monday after mid-stage data for its obesity pill topped competing offerings from ...

Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk

Shares of Texas-based biotech firm iBio ($IBIO) have climbed as high as 50% over the past 24 hours. This follows a 39.17% gain on Monday and an add...

Why is Biotech Stock iBio Up over 50%?

Shares in biotech firm Wave Life Sciences ($WVE) skyrocketed as high as 135% to over $17 on Monday. This came after initial results from the compan...

Wave Life Sciences Stock (WVE) Soars 135% on Obesity Drug Results

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novo Nordisk, with a price target of DKK295.00. Weston covers the H...

UBS Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

The share price has rallied over the past month.


Eli Lilly Stock (LLY) Gets Multiple Price Target Increases as Rally Continues

British drugmaker AstraZeneca ($AZN), fresh off a record-high stock price, continues to draw interest from U.S. and European investors thanks to, a...

Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?

Bank of America Securities analyst Sachin Jain reiterated a Hold rating on Novo Nordisk yesterday and set a price target of DKK340.00. The company’...

Novo Nordisk (0QIU) Receives a Hold from Bank of America Securities

Shares in weight-loss jab firms Novo Nordisk ($NVO) and Eli Lilly ($LLY) looked a little thinner today as the World Health Organization (WHO) decla...

NVO,LLY: Shares Drop as Word Health Organization Calls for Cheaper Versions of Weight-Loss Drugs

Novo Nordisk ( ($NVO) ) has risen by 8.32%. Read on to learn why. Novo Nordisk’s stock has seen an impressive 8.32% rise over the past week, driven...

Novo Nordisk’s Stock Surges Amid Drug Breakthrough

It has become increasingly difficult to find a job in the current economic climate, as many companies are slowing down hiring while trying to avoid...

As America’s Job Market Cracks, Here Are the Layoff Announcements You Can’t Ignore

In a report released on November 25, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk, with a price target of DKK510.00. The...

Kepler Capital  Keeps Their Buy Rating on Novo Nordisk (0QIU)

Investors will find all of the latest stock news to read before markets close for Thanksgiving.


Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Shares of Novo Nordisk ($NVO) are up 3% at the time of writing after the Centers for Medicare & Medicaid Services (CMS) announced price cuts across...

Novo Nordisk Stock (NVO) Jumps after Ozempic and Wegovy Prices Cut 71% under Medicare Plan

Novo Nordisk ( ($NVO) ) has shared an update. Novo Nordisk announced positive results from a phase 2 clinical trial of amycretin, a new treatment f...

Novo Nordisk Reports Positive Phase 2 Results for Amycretin in Type 2 Diabetes

Traders will find all of the deals, analyst ratings, and government updates moving shares on Monday in our daily roundup.


Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

An update from Novo Nordisk ( ($NVO) ) is now available. On November 24, 2025, Novo Nordisk announced the results of its evoke and evoke+ phase 3 t...

Novo Nordisk’s Alzheimer’s Trials Show No Significant Progress

Jefferies analyst Michael Leuchten maintained a Sell rating on Novo Nordisk today and set a price target of DKK290.00. According to TipRanks, Leuch...

Jefferies Remains a Sell on Novo Nordisk (0QIU)

Shares of Danish pharmaceutical Novo Nordisk ($NVO) traded flat on Friday afternoon after its key U.S.-based rival Eli Lilly ($LLY) reached $1 tril...

Novo Nordisk Stock (NVO) Under Pressure as Rival Eli Lilly Joins the $1 Trillion Club

Novo Resources ( ($TSE:NVO) ) has issued an announcement. Novo Resources has released its 2025 Sustainability Report, emphasizing its commitment to...

Novo Resources Unveils 2025 Sustainability Report, Emphasizing Integrity and Environmental Commitment

Pfizer Inc. ($PFE) is returning to the U.S. debt markets with a fresh corporate bond offering aimed at raising at least $5 billion, Bloomberg repor...

Pfizer (PFE) Taps Bond Market for $5 Billion to Fund Metsera Acquisition

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novo Nordisk, with a price target of DKK315.00. According to TipRan...

The latest announcement is out from Novo Nordisk ( ($NVO) ). On November 17, 2025, Novo Nordisk announced transactions involving its shares by boar...

Novo Nordisk Announces Insider Share Transactions

Eli Lilly Stock (LLY) Falls as Rival Novo Nordisk Cuts Weight-Loss Drug Prices

Novo Nordisk ( ($NVO) ) has provided an update. On November 14, 2025, Novo Nordisk A/S held an Extraordinary General Meeting to elect new members t...

Novo Nordisk Announces New Board Leadership Following Extraordinary Meeting

Investors continued to dump shares of telehealth company Mangoceuticals ($MGRX) during early trading on Friday. This came after pharmaceutical heav...

Investors Flee Mangoceuticals Stock (MGRX) after Eli Lilly and Novo Nordisk Deny Partnership

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Buy rating on Novo Nordisk, with a price target of $62.00. The compa...

Berenberg Bank Remains a Buy on Novo Nordisk (NVO)

Hims & Hers Health’s ($HIMS) shares continued to plunge on Thursday despite the consumer telehealth company launching a new “affordable” healthcare...

Hims & Hers Stock (HIMS) Plunges despite New ‘Affordable’ Healthcare Platform

Pfizer’s shares ($PFE) edged higher on Thursday after shareholders of Metsera ($MTSR) approved the American pharma giant’s offer of up to $10 billi...

Market Cap	$207.00B	P/E Ratio	14.02
52W High	$109.88	52W Low	$43.08
Div Yield	117.0%	Payout Ratio	N/A
EPS Growth 3Y	29.7%	52W Position	10.6%
Overall Score	53	Value Score	60
Quality Score	60	Technical Score	40

EPS Current Est	$3.58	EPS Next Est	$3.65
EPS Growth Est	+2.0%	DPS Growth 3Y	29.9%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVO	$50.18	-0.22%	12.39M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVO	$50.18	-0.2%	12.39M
3
4
5
6

NVO

NVO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Novo Nordisk A/S Data in Excel

Get Novo Nordisk A/S Data in Excel